dr. Bert Dhondt (MD)

CRIG member
Bert Dhondt

PhD Researcher - Laboratory for Experimental Cancer Research (Ugent)
Urology Resident - Department of Uro-Gynaecology (UZ Gent)
Principal investigators: prof. Olivier De Wever (PhD) & prof. Nicolaas Lumen (MD, PhD)

Research focus

Prostate cancer (PCa) is the most common malignancy and the second most common cause of cancer death in men in the Western world. Androgen-deprivation therapy (ADT) is used as a first step in the systemic treatment of PCa escaping local treatments. Despite the often initially good response, progression towards metastatic castration-refractory prostate cancer (mCRPC) is almost unavoidable. In spite of several new systemic treatments improving survival for patients witch mCRPC, the global response rate is only 30-60% for each line of therapy. Adequate patient selection for these treatments, early switch to another treatment in case of failure and optimal sequencing of these treatments are important objectives for research in PCa.



  •   Bachelor of Science in Medicine, Magna cum laude (2011)
  •   Master of Medicine, Magna cum laude (2015)
  •   Good Clinical Practice training (2016)
  •   Laboratory Animal Sciences (2016)
  •   Master of Medicine in Specialist Medicine, Urology (Ongoing)
  •   PhD training (Ongoing)

Key publications

  • Function of extracellular vesicle-associated miRNAs in metastasis'. Cell and Tissue Research, 2016. (PMID: 27289232)

Contact & links